GTL Shortlisted for Cancer Research Horizons New Startup of the Year Award
GTL's AI biomarker platform recognized for its potential to revolutionize cancer diagnosis and treatment.
from the frontier in AI biomarkers
Daniel Royston, pathology lead at Ground Truth Labs, to discuss AI-driven analysis of morphological biomarkers for trials in haemato-oncology.
Presenting our latest research at American Society of Hematology 2024.
GTL's AI biomarker platform recognized for its potential to revolutionize cancer diagnosis and treatment.
Ground Truth Labs highlights ASH 2023's innovative MPN therapies and advances AI-driven fibrosis assessment to revolutionize treatment approaches.
VP Business Development
Daniel Royston, pathology lead at Ground Truth Labs, discusses the role of AI in bone marrow histology with MPN Hub.
Pathology Lead
The vital role of novel research and development in tackling blood cancers like myeloproliferative neoplasms and myeloma.
AI biomarkers will transform oncology with new maps for tumor biology and breakthrough predictors for treatment response. We have the opportunity to improve outcomes for every cancer patient with AI-driven insights from digital pathology.
Co-founder
Today, Ground Truth Labs (GTL), is thrilled to announce its launch into the wider healthtech space. Backed by a $4.3M funding round led by Oxford Science Enterprises